Solutions / Investment and M&A
Investment IntelligenceMarket trends and investment intelligence for drug development
Track macro trends, market shifts, and subsector growth rates across drug development to spot investment opportunities and changing dynamics early, before they show up in the headlines.
- 610,000+ trials
- Refreshed daily
- Source-traceable
- Deep China coverage
Spot where drug development is heading
See where trial activity is accelerating or cooling across indications, modalities, geographies, sponsors, and more.
Track subsector trends
Follow trial activity, growth rates, and shifts across indications, modalities, and mechanisms. Filter for specific sponsors and geographies to tune your model assumptions with specific input fit for purpose.
Size and time opportunities
See where activity is accelerating or cooling, and verify trends in real-time. Calibrate the hype around the Chinese biopharma ecosystem and emerging antibody-drug conjugates. Keep a pulse on the continued ebbs and flows in cell and gene therapy.
An example trend, ready in minutes
ADC market trends
+21.2% CAGR
Antibody-drug conjugate trial starts have compounded 21.2% a year since 2019, one of oncology's fastest-growing modalities.
- 1Merck & Co.49 trials
- 2AstraZeneca48 trials
- 3Sichuan Baili46 trials
- 4Fudan University37 trials
- 5Daiichi Sankyo37 trials
ADC Trial Starts by Year
Global interventional and observational trials, count
| Year | Trial starts |
|---|